Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

JGAD000847

Type of data
NGS (Target Capture, RNA-seq)
Access criteria
Controlled-access (Type I)
Total data volume
283 GB
File formats
  • BAM
  • TXT
  • CSV
Research
hum0460
Date published
2025-01-30
Date modified
2025-01-30
DDBJ Search
JGAD000847 (opens in a new tab)
JGA Study
JGAS000714 (opens in a new tab)

Analysis method

Targeted DNA sequencing

Materials and participants
advanced urothelial carcinoma (ICD10: C66, C67): 82 cases
plasma cfDNA: 158 samples
tumor tissues: 73 samples
  • Health status
    Affected
  • Subject count
    82 (Individual)
Disease
advanced urothelial carcinoma (C66, C67)
Sample description
plasma cfDNA and DNAs extracted from tumor tissues
  • Tissue
    Plasma
  • Tumor / normal
    Mixed
Sample provider
N/A
Experimental method
Targeted DNA sequencing
Target
53 UC-relevant genes and TERT promoter
AKT1, AKT2, AKT3, ARID1A, ASXL2, ATM, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK4, CDK6, CDKN1A, CDKN2A, CREBBP, E2F3, EGFR, ELF3, EP300, ERBB2, ERBB3, ERCC2, FAT1, FBXW7, FGFR1, FGFR3, JAK1, JAK2, KDM6A, KMT2A, KMT2C, KMT2D, MAP2K4, MDM2, NF1, PBRM1, PIK3A, PPARG, PTEN, RAC1, RAF1, RAS, RB1, SPTAN1, STAG2, TERT, TP53, TSC1, TSC2, MLH1, MSH2, MSH6, PMS2
Reagent kit
ThruPLEX Tag-Seq Kit
Fragmentation
Ultrasonic fragmentation (Covaris S220)
Platform
Illumina HiSeq X
Illumina NovaSeq 6000
Read type
Paired-end
Read length
200 bp
Reference genome
GRCh37
Mapping
eVIDENCE pipline
Mapping quality
N/A
Analysis method
eVIDENCE pipline
Coverage (depth)
1086x
Variant count
683
Data use policy
NBDC data sharing policy (JGAP000001)

RNA-seq

Materials and participants
advanced urothelial carcinoma (ICD10: C66, C67): 82 cases
tumor tissues: 68 samples
  • Health status
    Affected
  • Subject count
    82 (Individual)
Disease
advanced urothelial carcinoma (C66, C67)
Sample description
RNAs extracted from tumor tissues
  • Tumor / normal
    Tumor
Sample provider
N/A
Experimental method
RNA-seq
Target
N/A
Reagent kit
TruSeq Stranded mRNA Library Prep Kit
Fragmentation
Exposure to divalent cations at elevated temperatures
Platform
Illumina NovaSeq 6000
Read type
Paired-end
Read length
200 bp
Reference genome
GRCh37
Mapping
Genomon 2.6.3
Mapping quality
N/A
QC and filtering
Genomon 2.6.3
Analysis method
Genomon 2.6.3
Data use policy
NBDC data sharing policy (JGAP000001)